- Parties: The plaintiff was Salix Pharmaceuticals, Inc. The defendant was Sandoz Canada Inc.

- Subject Matter: This is a Federal Court action commenced pursuant to subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations. The defendant’s pleading states that the action concerns Canadian Patent No. 2,739,436 in relation to ZAXINE and Sandoz’s abbreviated new drug submission for its proposed rifaximin product. A case management conference was directed to take place virtually via Zoom on June 12, 2026, and the case is ongoing.

- Date: The hearing was set on October 7,2026.

- Venue: This was a federal case before the Federal Court.

- Amount: No financial award was specified.